Cargando…
Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.
Autores principales: | Kosaka, Makoto, Ozaki, Akihiko, Kaneda, Yudai, Saito, Hiroaki, Yamashita, Erika, Murayama, Anju, Mamada, Hanano, Tanimoto, Tetsuya, Jakovljevic, Mihajlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230667/ https://www.ncbi.nlm.nih.gov/pubmed/37259132 http://dx.doi.org/10.1186/s12962-023-00441-z |
Ejemplares similares
-
Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
por: Hashimoto, Takanao, et al.
Publicado: (2022) -
Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
por: Mamada, Hanano, et al.
Publicado: (2023) -
Characteristics of Top-Searched Individuals in Japan’s Yen for Docs Conflicts of Interest Database During the COVID-19 Pandemic
por: Kaneda, Yudai, et al.
Publicado: (2023) -
Rethinking Japan’s Infallibility Principle for a Better Pandemic Response
por: Kaneda, Yudai, et al.
Publicado: (2023) -
Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)